{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:21:33Z","timestamp":1770272493762,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111586","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T20:04:53Z","timestamp":1706904293000},"page":"111586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study"],"prefix":"10.1016","volume":"129","author":[{"given":"Murat","family":"Bekta\u015f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Ay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Hamdi Uyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"\u0130kbal K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2024.111586_b0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J. Med. Virol."},{"issue":"19","key":"10.1016\/j.intimp.2024.111586_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911740","article-title":"Cytokine storm-definition, causes, and implications","volume":"23","author":"Jarczak","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2024.111586_b0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018Cytokine Storm' in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.intimp.2024.111586_b0020","doi-asserted-by":"crossref","unstructured":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-45. Doi: 10.1016\/s0140-6736(21)00676-0.","DOI":"10.1016\/S0140-6736(21)00676-0"},{"issue":"10","key":"10.1016\/j.intimp.2024.111586_b0025","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.111586_b0030","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1093\/rheumatology\/keaa728","article-title":"Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients","volume":"60","author":"Marko","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.intimp.2024.111586_b0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.55563\/clinexprheumatol\/fsq5vq","article-title":"The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature","volume":"39","author":"Giacomelli","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.111586_b0040","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.111586_b0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111586_b0050","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2024.111586_b0055","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111586_b0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12969-021-00585-3","article-title":"Intravenous administration of anakinra in children with macrophage activation syndrome","volume":"19","author":"Phadke","year":"2021","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"8","key":"10.1016\/j.intimp.2024.111586_b0065","doi-asserted-by":"crossref","first-page":"e12697","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.intimp.2024.111586_b0070","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.111586_b0075","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2022 [Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"issue":"12","key":"10.1016\/j.intimp.2024.111586_b0080","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1016\/S2665-9913(20)30343-X","article-title":"Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study","volume":"2","author":"Webb","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111586_b0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10787-023-01138-8","article-title":"High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center","volume":"31","author":"Bekta\u015f","year":"2023","journal-title":"Inflammopharmacology"},{"issue":"12","key":"10.1016\/j.intimp.2024.111586_b0090","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00228-022-03402-2","article-title":"JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study","volume":"78","author":"Gouverneur","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111586_b0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2024.111586_b0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14740338.2023.2223955","article-title":"Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)","volume":"22","author":"Mytheen","year":"2023","journal-title":"Expert. Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.intimp.2024.111586_b0105","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jaci.2022.05.029","article-title":"Spontaneous NLRP3 inflammasome-driven IL-1-\u03b2 secretion is induced in severe COVID-19 patients and responds to anakinra treatment","volume":"150","author":"Bertoni","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"19","key":"10.1016\/j.intimp.2024.111586_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194462","article-title":"The effect of anakinra in hospitalized patients with COVID-19: An updated systematic review and meta-analysis","volume":"10","author":"Kyriakoulis","year":"2021","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.111586_b0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00325481.2020.1855921","article-title":"JAK-STAT pathway inhibition and their implications in COVID-19 therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad. Med."},{"issue":"10","key":"10.1016\/j.intimp.2024.111586_b0120","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jcph.1874","article-title":"Baricitinib: From rheumatoid arthritis to COVID-19","volume":"61","author":"Assadiasl","year":"2021","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2024.111586_b0125","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:42:04Z","timestamp":1769229724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924001048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"alternative-id":["S1567576924001048"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111586","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111586"}}